Tinzaparin - Clinical Resources
Transitioning to Tinzaparin - Effective September 27, 2022
- All SHA sites transitioned to using tinzaparin as the low molecular weight heparin (LMWH) for most indications. Simultaneously, there was a switch to using enoxaparin REDESCA (a biosimilar agent) for the remaining indications.
Learning Module - Transitioning to Tinzaparin
-
-
Transition to Tinzaparin - A Provincial Approach
ALERT: Log in to MyConnection prior to accessing any learning module to ensure completion is recorded in the system.
Tinzaparin in Hemodialysis
Clinical Procedure
-
-
Transitioning to Tinzaparin for Hemodialysis Circuit Patency (CS-LM-0072)
ALERT: Log in to MyConnection prior to accessing any learning module to ensure completion is recorded in the system.
